Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Nov 2023

Pranteda Angelina, Piastra Valentina, Serra Martina, Bernardini Roberta, Lo Sardo Federica, Carpano Silvia, Diodoro Maria Grazia, Bartolazzi Armando, Milella Michele, Blandino Giovanni, Bossi Gianluca

Abstract excerpt

Colorectal cancer (CRC) patients with BRAF mutations develop resistance to BRAF inhibitors at a very early stage. Understanding the molecular mechanisms involved in BRAF inhibitor resistance is critical for the development of novel therapeutic opportunities for this subtype of CRC patients. CRC cells bearing BRAF mutations are mostly sensitive to the abrogation of Mitogen-Activated Protein Kinase Kinase 3 (MKK3),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Oximes

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-myc

Share to Signal Transduction

Source

Identifiers

PMID: 37713993
DOI: 10.1016/j.biopha.2023.115480

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.PMID 37713993Read ↗

Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistanceSemantic proximity Read ↗

MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancerSemantic proximity Read ↗

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read ↗

Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.Semantic proximity Read ↗

AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.Semantic proximity Read ↗

BRAF inhibitors in cancer therapy.Semantic proximity Read ↗

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read ↗

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activationSemantic proximity Read ↗

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistanceSemantic proximity Read ↗

BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.